Notably, genetic depletion or pharmacological inhibition of SLC7A11 induces synthetic lethality in KRAS-mutant lung adenocarcinoma, highlighting SLC7A11 as a potential therapeutic target for RAS-driven tumors [51]. The gene discussed is KRAS; the disease is lung adenocarcinoma.